EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Risks of Undertreatment and Overtreatment in Pediatric Inflammatory Bowel Disease: Navigating the Balance

Giulia D'Arcangelo, Silvana Ancona, Giulia Naspi Catassi, Francesca Musto, Rosaria Celano, Marina Aloi

Pediatric Drugs · 2026-07 · 28 (4) · 331-342

DOI: 10.1007/s40272-026-00751-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Drugs, online erschienen am 11.06.2026. Verfasst von Giulia D'Arcangelo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology, Hepatology and Cystic Fibrosis Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico di Milano, Milan, Italy. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Overtreatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Università degli Studi di Milano.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite major therapeutic advances in recent years, and early signs that the overall standard of care we can deliver to children with inflammatory bowel disease (IBD) is improving, the promise of precision medicine remains largely unfulfilled in daily practice. The goal is to match the right therapy to the right patient, in the right time window, so that treatment intensity reflects true disease biology and future risk rather than broad population averages. However, this approach is still an unmet need. Even when management is framed within a risk-based paradigm, clinical decisions are often guided by generalized recommendations and imperfect predictors, with limited capacity to individualize strategies at diagnosis and during follow-up. As a result, two opposite but equally relevant pitfalls remain very real. On one hand, overtreatment can lead to unnecessary exposure to immunosuppressive regimens in children and adolescents with mild, slowly progressive, or self-limited disease, increasing the burden of adverse events, monitoring, and psychosocial impact. On the other hand, undertreatment in truly high-risk patients can delay effective control of inflammation, allowing ongoing tissue damage, disease extension, growth impairment, and avoidable complications, ultimately worsening long-term outcomes. This critical review summarizes and critically appraises current recommendations and available evidence, focusing on the pitfalls of overtreatment and undertreatment in pediatric IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesOvertreatmentHumansChildUndertreatmentAdolescentImmunosuppressive Agents

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Gastroenterology, Hepatology and Cystic Fibrosis Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico di Milano, Milan, Italy.
  • Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
  • Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy. marina.aloi@unimi.it.
  • Gastroenterology, Hepatology and Cystic Fibrosis Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico di Milano, Milan, Italy. marina.aloi@unimi.it.

Förderung

  • Università degli Studi di Milano

Zitieren

APA

D'Arcangelo, G., Ancona, S., Naspi Catassi, G., Musto, F., Celano, R., & Aloi, M. (2026). Risks of Undertreatment and Overtreatment in Pediatric Inflammatory Bowel Disease: Navigating the Balance. Pediatric Drugs, 28(4), 331-342. https://doi.org/10.1007/s40272-026-00751-8

Vancouver

D'Arcangelo G, Ancona S, Naspi Catassi G, Musto F, Celano R, Aloi M. Risks of Undertreatment and Overtreatment in Pediatric Inflammatory Bowel Disease: Navigating the Balance. Pediatric Drugs. 2026;28(4):331-342. doi:10.1007/s40272-026-00751-8

BibTeX
@article{DArcangelo2026,
  author = {D'Arcangelo, Giulia and Ancona, Silvana and Naspi Catassi, Giulia and Musto, Francesca and Celano, Rosaria and Aloi, Marina},
  title = {Risks of Undertreatment and Overtreatment in Pediatric Inflammatory Bowel Disease: Navigating the Balance},
  journal = {Pediatric Drugs},
  year = {2026},
  volume = {28},
  number = {4},
  pages = {331--342},
  doi = {10.1007/s40272-026-00751-8}
}
Kostenlos starten →